Fundraising Fox
🦊/People
Sign in

Jaume Pons

Investor

Venture Partner at venBio Partners · Board director at Tallac Therapeutics

Burlingame, California

Writes $20M – $30M checks · typically $25M

Find your path to Jaume

438 people in our graph share verified history with Jaume — schools, employers, funds. One of them is your warm intro.

Anthony LinunlockedJaume: together at University of California, Berkeley (1996)
×4Jaume: together at University of California, Berkeley
×7Jaume: together at Universitat de Barcelona

About

Jaume Pons personally invented Ajovy (an anti‑CGRP antibody commercialized by Teva), led 13 protein therapeutics into human trials, and co‑founded ALX Oncology, taking it from inception through IPO.

Invests in

BiotechHealthtech

Board director at Tallac Therapeutics

Intro paths

→

In turn, Jaume can intro founders to Tallac Therapeutics's investors below.

Tallac Therapeutics's investors · 5

Lightstone VenturesPortola ValleyMatrix Partners ChinaBeijing · $1.6M – $113M checksMRL Ventures FundCambridge · $25M checksvenBio Global StrategicSan Francisco · since 2021venBio PartnersSan Francisco · since 2020

Co-founders at Tallac Therapeutics

HWHong Wan
Hong WanExecutive Officer, Director

Experience

  1. venBioVenbio Venture partnercurrent2015 — presentUnited States
  2. ALX OncologyPresident and CSO2023 — 2025San Francisco Bay Area
  3. ALX OncologyPresident and CEO2015 — 2023Burlingame, CA
  4. ALX OncologyPresident and CEO2015 — 2023Burlingame, CA
  5. Rinat (Pfizer)Pfizer SVP and Rinat CSO2009 — 2015South San Francisco. CA
  6. Rinat (Pfizer)VP and Rinat CSO2008 — 2009
  7. Rinat (Pfizer)Chief Scientific Officer, Rinat2007 — 2009
  8. ChironScientist 21999 — 2002
  9. UC BerkeleyPosdoc (Kirsch lab)1996 — 1999

Skills & more

Biotechnology38Drug Development21Drug Discovery31Lifesciences9Clinical Development8Biopharmaceuticals8Protein Chemistry13Technology Transfer5Biochemistry4R&D6Immunology9Life Sciences14
+5 morePharmaceutical IndustryAssay DevelopmentMolecular BiologyOncologyMonoclonal Antibodies

From Jaume's professional profile.

Deals · 1

Alexo TherapeuticsBoard seat

via venBio Partners · filed May 2015 · $36M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Per SEC Form D filings.

Colleagues at venBio Partners

Aaron Royston
Managing Partner at venBio Partners
Behzad Aghazadeh
Executive Officer at venBio Partners
Corey Goodman
Co-founder and Managing Partner at venBio Partners
Daniel Teichmann
Controller at venBio Partners
David Pezeshki
Chief Financial Officer at venBio Partners
Neil Cammarosano
Executive Officer at venBio Partners
Parthiv Patel
Analyst at venBio Partners
Richard Gaster
Managing Partner at venBio Partners

Network2

Aaron Royston
Managing Partner at venBio Partners
Corey Goodman
Co-founder and Managing Partner at venBio Partners

Investors connected to Jaume in public investor directories — a warm-intro map.

Frequently asked questions

Who is Jaume Pons?
Jaume Pons personally invented Ajovy (an anti‑CGRP antibody commercialized by Teva), led 13 protein therapeutics into human trials, and co‑founded ALX Oncology, taking it from inception through IPO.
Where does Jaume Pons work?
Jaume Pons is Venture Partner at venBio Partners and Board director at Tallac Therapeutics.
What does Jaume Pons invest in?
Jaume Pons invests in Biotech, Healthtech.
What check size does Jaume Pons write?
Jaume Pons typically writes checks of $20M – $30M.
What boards does Jaume Pons sit on?
Jaume Pons holds tracked board seats at Alexo Therapeutics, Tallac Therapeutics.
Where did Jaume Pons go to school?
Jaume Pons studied at University of California, Berkeley (Postdoc, Protein Engineering); Universitat de Barcelona.

Founder mafias

Same school

Shared employers